

# PRV

PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

PCT / SE 2004 / 001421

REC'D 26 OCT 2004

WIPO

PCT

## Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.


(71) Sökande                      AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer    0302667-1  
Patent application number

(86) Ingivningsdatum                      2003-10-07  
Date of filing

Stockholm, 2004-10-08

För Patent- och registreringsverket  
For the Patent- and Registration Office

  
Görel Gustafsson

Avgift  
Fee

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

**PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN**

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

## NOVEL COMPOUNDS

### Field of the Invention

- 5 The present invention discloses novel 2-substituted 4-amino-5,6-fused-pyrimidine derivatives together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy.

### Background of the Invention

10

Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases and inflammatory bowel disease (IBD), as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa  
15 proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These two groups are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

20

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (CXCL8) and neutrophil-activating peptide 2 (CXCL7).

25

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (CCL2, CCL7 and CCL8), RANTES (CCL5), eotaxin (CCL11) and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (CCL3 and CCL4).

There is also a third chemokine family based upon the structural motif Cys-X<sub>3</sub>-Cys

(C-X<sub>3</sub>-C). This C-X<sub>3</sub>-C family is distinguished from the C-X-C and C-C families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues. CX<sub>3</sub>CL1 (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system as well as of monocytes, T cells, NK cells and mast cells.

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors. In particular, the actions of CX<sub>3</sub>CL1 are mediated by the CX<sub>3</sub>CR1 receptor.

10

WO 01/62758 discloses certain 2-substituted 4-amino-7(8H)-pteridinone derivatives that are useful as antagonists of receptors linked to the C-X-C and C-C chemokine families, particularly as antagonists of the CXCR2 receptor. WO 00/09511 and WO 01/58907 disclose certain 2-substituted 4-amino-thiazolopyrimidine derivatives that are useful as antagonists of receptors linked to the C-X-C and C-C chemokine families, particularly as antagonists of the CXCR2 receptor.

The present invention relates to a group of compounds that are structurally similar to, but nevertheless generically distinct from, the compounds disclosed in WO 00/09511, WO 01/58907 and WO 01/62758. The compounds of the present invention display surprisingly useful properties as antagonists of the CX<sub>3</sub>CR1 receptor.


20

#### Disclosure of the invention

25

The present invention provides compounds of formula (I)


3




(I)

wherein:

5 A represents a group of formula (a) or (b):



(a)



(b)

10  $R^1$  and  $R^2$  independently represent H, C1 to 8 alkyl, C2 to 8 alkenyl, C2 to 8 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; the latter four groups being optionally further substituted by one or more groups selected independently from OH, C1 to 6 alkoxy,  $CH_2OR^4$ ,  $NR^5R^6$ ,  $CO_2R^7$  and  $CONR^8R^9$ ;

15  $R^3$  represents C1 to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or alkynyl chain optionally including a O,  $NR^{10}$  or S atom in the chain; said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by phenyl or a 5 or 6 membered heteroaromatic ring containing 1 to 3 heteroatoms selected independently from O, S and N; said phenyl or heteroaromatic ring being optionally further substituted by one or more groups selected independently from  
20 halogen, C1 to 4 alkyl, OH, C1 to 4 alkoxy, CN,  $CO_2R^{11}$ ,  $NR^{12}R^{13}$ ,  $CONR^{14}R^{15}$ ,  $SO_2R^{16}$ ,  $NR^{17}SO_2R^{18}$  and  $SO_2NR^{19}R^{20}$ ;

X represents O or S(O);

$R^{21}$  represents H,  $CH_2OR^{24}$ ,  $CH_2NR^{24}R^{25}$ ,  $CO_2R^{24}$  or  $CONR^{24}R^{25}$ ;

5  $R^{22}$  and  $R^{23}$  independently represent H, C1 to 6 alkyl, C2 to 6 alkenyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or cycloalkyl group being optionally substituted by  $OR^{24}$ ,  $NR^{24}R^{25}$ ,  $CO_2R^{24}$  or  $CONR^{24}R^{25}$ ; or the group  $-NR^{22}R^{23}$  together  
10 represents a 3 to 7 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O,  $S(O)_n$  and  $NR^{26}$ ; and optionally substituted by  $OR^{24}$ ,  $NR^{24}R^{25}$ ,  $CO_2R^{24}$  or  $CONR^{24}R^{25}$ ;

n represents an integer 0, 1 or 2;

15  $R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{24}, R^{25}$  and  $R^{26}$  independently represent H or C1 to 6 alkyl;

and pharmaceutically acceptable salts thereof.

20 The compounds of formula (I) may exist in enantiomeric and/or tautomeric forms. It is to be understood that all enantiomers, diastereomers, racemates, tautomers and mixtures thereof are included within the scope of the invention.

25 Unless otherwise indicated, the term "C1 to 8 alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 8 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl and hexyl. The terms "C1 to 6 alkyl" and "C1 to 4 alkyl" are to be interpreted analogously.

30 Unless otherwise indicated, the term "C2 to 8 alkenyl" referred to herein denotes a straight or branched chain alkyl group having from 2 to 8 carbon atoms and containing one carbon-carbon double bond. The term "C2 to 6 alkenyl" is to be interpreted analogously.

Unless otherwise indicated, the term "C2 to 8 alkynyl" referred to herein denotes a straight or branched chain alkyl group having from 2 to 8 carbon atoms and containing one carbon-carbon triple bond. The term "C2 to 6 alkenyl" is to be interpreted analogously.

5 Unless otherwise indicated, the term "C3 to 7 saturated or partially unsaturated cycloalkyl" referred to herein denotes a 3 to 7 membered non-aromatic carbocyclic ring optionally incorporating one or more double bonds. Examples include cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl.

10 Unless otherwise indicated, the term "C1 to 6 alkoxy" referred to herein denotes an oxygen substituent bonded to a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy and s-butoxy. The term "C1 to 4 alkoxy" is to be interpreted analogously.

15

Unless otherwise indicated, the term "halogen" referred to herein denotes fluorine, chlorine, bromine and iodine.


20 Examples of a five or six membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N include furan, thiophene, pyrrole, oxazole, oxadiazole, isoxazole, imidazole, thiazole, triazole, thiadiazole, pyridine, pyrimidine and pyrazine.

25 Examples of a 3 to 7 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, S and N include pyrrolidine, piperidine, morpholine and piperazine.

30 In the definition of  $R^3$ , the expression "said alkyl, alkenyl or alkynyl chain optionally including a O,  $NR^{10}$  or S atom in the chain" embraces a straight or branched chain arrangement of 1 to 6 carbon atoms in which, where chemically feasible, the carbon chain is interrupted by, or terminates in, an O, S or  $NR^{10}$  atom. The definition thus includes, for


example, methylene, ethylene, propylene, hexamethylene, ethylethylene,  $-\text{CH}_2\text{CH}_2\text{O}-$   
 $\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{O}-\text{CH}_2-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{S}-$  and  $-\text{CH}_2\text{CH}_2\text{NR}^{10}-$ .

In one embodiment of the invention, A represents a group of formula (a). That is,  
 5 compounds of formula (Ia):



(Ia)

In another embodiment of the invention, A represents a group of formula (b). That is,  
 10 compounds of formula (Ib):



(Ib)

15 In one embodiment, X represents O. In another embodiment, X represents S(O).

In one embodiment,  $\text{R}^{21}$  represents H,  $\text{CO}_2\text{R}^{24}$  or  $\text{CO}_2\text{NR}^{24}\text{R}^{25}$ . In another embodiment,  $\text{R}^{21}$  represents H.

In one embodiment,  $R^{22}$  and  $R^{23}$  independently represent H or optionally substituted C1 to 3 alkyl. In another embodiment,  $R^{22}$  and  $R^{23}$  each represent H.

In one embodiment,  $R^1$  and  $R^2$  independently represent H, optionally substituted C1 to 8 alkyl or optionally substituted C3 to 7 cycloalkyl.

In another embodiment,  $R^1$  represents H or  $CH_3$ . In another embodiment,  $R^1$  represents H.

In another embodiment  $R^2$  represents optionally substituted C1 to 8 alkyl or optionally substituted C3 to 7 cycloalkyl. In another embodiment,  $R^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $CH_2OR^4$ .

In one embodiment,  $R^3$  represents optionally substituted C1 to 6 alkyl that optionally includes an O atom in the chain. In another embodiment,  $R^3$  represents C1 to 6 alkyl optionally including an O atom in the chain and substituted by optionally substituted phenyl. In another embodiment,  $R^3$  represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

In one embodiment, A represents a group of formula (a), X represents O,  $R^1$  represents H or  $CH_3$ ;  $R^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $CH_2OR^4$ ; and  $R^3$  represents C1 to 6 alkyl substituted by optionally substituted phenyl.

In another embodiment, A represents a group of formula (a), X represents O,  $R^1$  represents H;  $R^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $CH_2OR^4$ ; and  $R^3$  represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

In one embodiment, A represents a group of formula (a), X represents S(O),  $R^1$  represents H or  $CH_3$ ;  $R^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted



by OH or  $\text{CH}_2\text{OR}^4$ ; and  $\text{R}^3$  represents C1 to 6 alkyl substituted by optionally substituted phenyl.

5 In another embodiment, A represents a group of formula (a), X represents S(O),  $\text{R}^1$  represents H;  $\text{R}^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $\text{CH}_2\text{OR}^4$ ; and  $\text{R}^3$  represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

10 In one embodiment, A represents a group of formula (b), X represents O,  $\text{R}^1$  represents H or  $\text{CH}_3$ ;  $\text{R}^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $\text{CH}_2\text{OR}^4$ ; and  $\text{R}^3$  represents C1 to 6 alkyl substituted by optionally substituted phenyl.

15 In another embodiment, A represents a group of formula (b), X represents O,  $\text{R}^1$  represents H;  $\text{R}^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $\text{CH}_2\text{OR}^4$ ; and  $\text{R}^3$  represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

20 In one embodiment, A represents a group of formula (b), X represents S(O),  $\text{R}^1$  represents H or  $\text{CH}_3$ ;  $\text{R}^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $\text{CH}_2\text{OR}^4$ ; and  $\text{R}^3$  represents C1 to 6 alkyl substituted by optionally substituted phenyl.

25 In another embodiment, A represents a group of formula (b), X represents S(O),  $\text{R}^1$  represents H;  $\text{R}^2$  represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or  $\text{CH}_2\text{OR}^4$ ; and  $\text{R}^3$  represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.

Particular compounds of formula (I) include:

(2*R*)-2-([2-amino-5-(benzyloxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

5 (2*R*)-2-([2-amino-5-(2-phenylethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-(2-phenoxyethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

10 (2*R*)-2-([2-amino-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-[(4-chlorobenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-[(3-chlorobenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

15 (2*R*)-2-([2-amino-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-(benzyloxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

20 3-([(2-amino-7-([(1*R*)-1-(hydroxymethyl)-3-methylbutyl](methyl)amino)[1,3]thiazolo[4,5-*d*]pyrimidin-5-yl]oxy)methyl]benzonitrile;

(2*R*)-([2-amino-5-[(4-bromo-2-fluorobenzyl)-(*R<sub>S</sub>*,*S<sub>S</sub>*)-sulfinyl][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-{[2-(3-chlorophenyl)ethyl]-(*R<sub>S</sub>*,*S<sub>S</sub>*)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

25 (2*R*)-2-([2-amino-5-{[2-(4-bromophenyl)ethyl]-(*R<sub>S</sub>*,*S<sub>S</sub>*)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

(2*R*)-2-([2-amino-5-{[2-(2-bromophenyl)ethyl]-(*R<sub>S</sub>*,*S<sub>S</sub>*)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol;

30 (*R*)-2-([2-amino-5-{[2-(2-bromophenyl)ethyl]-(*R<sub>S</sub>*,*S<sub>S</sub>*)-sulfinyl}[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol;

2-[(2,3-difluorobenzyl)oxy]-4-([(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino)pteridin-7(8*H*)-one;

4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]-2-[(3-methoxybenzyl)oxy]pteridin-7(8*H*)-one;

2-[(2-chloro-3-methoxybenzyl)oxy]-4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8*H*)-one;

5 4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]-2-(2-phenylethoxy)pteridin-7(8*H*)-one;

4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]-2-(2-phenoxyethoxy)pteridin-7(8*H*)-one;

10 2-[(2-chlorobenzyl)oxy]-4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8*H*)-one;

2-[(4-chlorobenzyl)oxy]-4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8*H*)-one;

4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]-2-[(4-methylbenzyl)oxy]pteridin-7(8*H*)-one;

15 4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]-2-[(3-methylbenzyl)oxy]pteridin-7(8*H*)-one;

4-[[4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]-7-oxo-7,8-dihydropteridin-2-yl]oxy]methyl]benzonitrile;

20 2-[(2-chlorobenzyl)oxy]-4-[[*(1S,2S)*-2-hydroxy-1-(hydroxymethyl)propyl]amino]-7-oxo-7,8-dihydropteridine-6-carboxamide;

2-[(3-chlorobenzyl)oxy]-4-[[*(1S,2S)*-2-hydroxy-1-(hydroxymethyl)propyl]amino]-7-oxo-7,8-dihydropteridine-6-carboxamide;


2-[(2,3-difluorobenzyl)-(R<sub>s</sub>,S<sub>s</sub>)-sulfinyl]-4-[[*(1R)*-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8*H*)-one;

25 and pharmaceutically acceptable salts thereof.

According to the invention, we further provide a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof which comprises:

30 (a) when X in formula (I) represents O, reaction of a compound of formula (II)


11



(II)

wherein A, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in formula (I);

with a compound of formula (III)




(III)

wherein R<sup>3</sup> is as defined in formula (I) and is independent of the R<sup>3</sup> group in formula (II);

or

(b) when X in formula (I) represents S(O), oxidation of a compound of formula (IV)



(IV)

wherein A, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in formula (I); with one equivalent of an oxidising agent;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

In process (a), the reactants (II) and (III) are coupled together in a suitable inert organic solvent such as tetrahydrofuran, benzene, toluene or N-methylpyrrolidine. The reaction is performed in the presence of an added base such as sodium hydride, butyl lithium or lithium diisopropylamide. The reaction is conducted at a suitable temperature, normally  
5 between room temperature and the boiling point of the solvent. The reaction is generally continued for a period of about one hour to one week, or until analysis indicates that formation of the required product is complete.

In process (b), the compound is oxidised using one equivalent of a suitable oxidising agent  
10 such as those known in the art for the oxidation of sulphides into sulfoxides. A preferred oxidant is oxone. The reaction is generally conducted at ambient temperature and in a suitable solvent such as methanol or aqueous acetonitrile.

Compounds of formula (I) and intermediate compounds thereto may be prepared as such or  
15 in protected form. Protecting groups that are suitable for particular functional groups and details of processes for adding and removing such protecting groups are, in general, well known in the art. See, for example, "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

20 The present invention includes compounds of formula (I) in the form of salts. Suitable salts include those formed with organic or inorganic acids or organic or inorganic bases. Such salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids or bases may be of utility in the preparation and purification of the compound in question. Thus, preferred acid addition salts include those formed from  
25 hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids. Preferred base addition salts include those in which the cation is sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, choline, ethanolamine or diethylamine.

30 Salts of compounds of formula (I) may be formed by reacting the free compound, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid or base. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a


solvent in which the salt is soluble, for example, water, dioxan, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed *in vacuo* or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.

5

Sulphone derivatives of formula (II) may be prepared by oxidation of the corresponding sulphides of formula (IV) using two or more equivalents of an oxidising agent such as oxone.

- 10 In general, compounds of formula (IV) may be prepared using known methods that will be readily apparent to the man skilled in the art. Some such methods are illustrated in Schemes 1 to 3:



Scheme 1




15

T  
E  
X  
T  
O  
N  
L  
Y

Scheme 2



Scheme 3



Intermediate compounds may be used as such or in protected form. Protecting groups and details of processes for their removal may be found by reference to the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

- 5 The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.

The compounds of formula (I) may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention.

- 10 The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC. Alternatively, the various optical isomers may be prepared directly using optically active starting materials.

- 15 Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.

- The compounds of formula (I), and their pharmaceutically acceptable salts are useful because they possess pharmacological activity as antagonists of the CX<sub>3</sub>CR1 receptor. In particular,  
20 when compared to similar sulphide derivatives disclosed in WO 00/09511, WO 01/58907 and WO 01/62758, the ether [formula (I); X = O] and sulfoxide [formula (I); X = S(O)] derivatives of the present invention possess significantly improved solubility profiles.

- 25 In one aspect the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a medicament.

- In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which antagonism of the CX<sub>3</sub>CR1  
30 receptor is beneficial.



In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis or pain.

5

In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of multiple sclerosis (MS).

10 According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

15

There is also provided a method of treating, or reducing the risk of, neurodegenerative disorders, demyelinating disease, atherosclerosis or pain in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a  
20 pharmaceutically acceptable salt thereof.

There is also provided a method of treating, or reducing the risk of, multiple sclerosis (MS) in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of  
25 formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent

or carrier, for use in the treatment or prophylaxis of diseases or conditions in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial.

In another aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis or pain.

In another aspect the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use in the treatment or prophylaxis of multiple sclerosis.

The compounds of formula (I) and their pharmaceutically acceptable salts are indicated for use in the treatment or prophylaxis of diseases or conditions in which modulation of activity at the CX<sub>3</sub>CR1 receptor is desirable. In particular, the compounds are indicated for use in the treatment of neurodegenerative disorders or demyelinating disease in mammals including man. . More particularly, the compounds are indicated for use in the treatment of multiple sclerosis. The compounds are also indicated to be useful in the treatment of pain, rheumatoid arthritis, osteoarthritis, stroke, atherosclerosis and pulmonary arterial hypertension.

Conditions that may be specifically mentioned are: neurodegenerative diseases and dementia disorders, for example, Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy, Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, for example, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and plexopathies; CNS demyelination, for example, acute disseminated/haemorrhagic encephalomyelitis and subacute sclerosing panencephalitis; neuromuscular disorders, for example, myasthenia gravis

and Lambert-Eaton syndrome; spinal disorders, for example, tropical spastic paraparesis and stiff-man syndrome; paraneoplastic syndromes, for example, cerebellar degeneration and encephalomyelitis; CNS trauma; and migraine.

- 5 Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly  
10 susceptible to developing the disease or condition.

The compounds of the invention are also indicated for use in the treatment of inflammatory bowel disease (IBD), for example, Crohn's disease and ulcerative colitis, by inducing remission and/or maintaining remission of IBD.

15

For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.

20

The compounds of formula (I) and pharmaceutically acceptable derivatives thereof, may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral,  
25 sublingual or rectal), intranasal, intravenous, topical or other parenteral routes.

Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a  
30 compound of formula (I), or a pharmaceutically acceptable salt thereof.

There is also provided a process for the preparation of such a pharmaceutical composition that comprises mixing the ingredients.

The invention is illustrated, but in no way limited, by the following examples:

5

#### General Procedures

Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Gemini 7 Tesla 300 MHz instrument, or a Bruker Avance 400 MHz instrument using the solvent indicated.

10 Chemical shifts are given in ppm down- and upfield from tetramethylsilane (TMS). Resonance multiplicities are denoted s, d, t, m, br and app for singlet, doublet, triplet, multiplet, broad and apparent, respectively. Mass spectra (MS) were recorded on a Finnigan SSQ7000 TSP or a Finnigan SSQ710 DI/EI instrument, or on a single quadrupole mass spectrometer, ZMD (Waters), using an electrospray ion source operated in a positive

15 mode. The ion spray voltage was +3 kV and the mass spectrometer was scanned from  $m/z$  100 – 900 with a scan time of 0.85s. LC-MS was performed with a Waters 2790 LC-system equipped with a Waters Xterra™ MS C<sub>8</sub> (2.5  $\mu$ m x 30 mm) column, a Waters 996 photodiode array detector and a Micromass ZMD. High pressure liquid chromatography (HPLC) assays were performed using a Hewlett Packard 1100 Series HPLC system

20 equipped with a Zorbax SB-C<sub>8</sub> (4.6 mm x 15 cm) column. Preparative high pressure liquid chromatography (prep HPLC) separations were performed on an automated Gilson (model 170) using an Xterra C<sub>18</sub> (19 mm x 30 cm) column, and using a gradient of A (water 95%, containing NH<sub>4</sub>OAc (0.01 M), and 5% CH<sub>3</sub>CN) and B (CH<sub>3</sub>CN) as eluent. Column chromatography was performed using silica gel 60 (230–400 mesh ASTM, Merck) and thin

25 layer chromatography (TLC) was performed on TLC precoated plates, silica gel 60 F<sub>254</sub> (Merck).

#### Example 1 (2R)-2-([2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino)-4-methylpentan-1-ol

30

#### (a) (2R)-2-([2-Amino-5-(benzylsulfonyl)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino)-4-methylpentan-1-ol

(2R)-2-([2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol (WO 00/09511) (1.0 g, 2.56 mmol) was dissolved in CH<sub>3</sub>CN (120 mL) and water (80 mL). Potassium peroxymonosulfate (Oxone, 3.38 g, 5.50 mmol) was added and the resulting slurry was stirred at RT for 16 h. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution was added and the CH<sub>3</sub>CN was evaporated. The residue was poured onto ice and the precipitate was collected by filtration, washed with water and dried *in vacuo* at 40 °C overnight resulting in 920 mg (85%) of the title compound as an off-white solid.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.40-8.19 (br s, 2H), 7.40-7.26 (m, 5H), 6.83 (d, 1H), 4.84 (d, 1H), 4.77 (d, 1H), 4.40 (br s, 1H), 3.62-3.43 (m, 3H), 1.63-1.39 (m, 3H), 0.91 (d, 3H), 0.84 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 422 [M+H]<sup>+</sup>.

(b) (2R)-2-([2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol

Solid NaH (17 mg, 0.7 mmol; 7 eq.) was added to a stirred solution of benzyl alcohol (76 mg, 0.7 mmol; 7 eq.) in dry benzene (5 mL) at 0 °C. The solution was allowed to reach RT over 15 min. The product of step (a) (42 mg, 0.1 mmol; 1 eq.) was added as a solid, and the mixture was heated to reflux for 1 h. After cooling to RT, the reaction was quenched by the addition of saturated NH<sub>4</sub>Cl solution (1 mL). The mixture was partitioned between THF (10 mL) and water (10 mL). The organic phase was separated, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated *in vacuo*. The oily residue was purified by preparative HPLC to give the title compound as an off-white solid (4.8 mg, 13%).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.04 (br s, 2H), 7.41-7.25 (m, 5H), 6.89 (d, 1H), 5.26 (s, 2H), 4.74-4.60 (m, 2H), 3.50-3.33 (m, 2H), 1.63-1.39 (m, 2H), 1.27 (m, 1H), 0.90 (d, 3H), 0.83 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 374 [M+H]<sup>+</sup>.

The compounds of Examples 2 to 4 were prepared using the general method of Example 1, step (b), but replacing benzyl alcohol with the appropriate alcohol.

**Example 2** (2*R*)-2-([2-Amino-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol

Off-white solid (4.4 mg, 11% yield).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.11 (br s, 2H), 7.39-7.33 (2H), 7.10 (d, 1H), 6.95 (s, 1H) 6.80 (d, 1H), 5.26 (s, 2H), 4.77-4.57 (m, 2H), 3.48-3.39 (m, 2H), 3.33 (s, 3H), 1.55-1.37 (m, 2H), 1.26 (m, 1H), 0.89 (d, 3H), 0.83 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 404 [M+H]<sup>+</sup>.

**Example 3** (2*R*)-2-([2-Amino-5-(2-phenylethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol

Off-white solid (6.2 mg, 16% yield).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.10 (br s, 2H), 7.35-7.22 (m, 5H), 6.83 (d, 1H), 4.83 (t, 2H), 4.77-4.50 (m, 2H), 3.58-3.44 (m, 2H), 3.23 (t, 2H), 1.50-1.39 (m, 2H), 1.29 (m, 1H), 0.89 (d, 3H), 0.84 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 388 [M+H]<sup>+</sup>.

**Example 4** (2*R*)-2-([2-Amino-5-(2-phenoxyethoxy)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl]amino)-4-methylpentan-1-ol

Clear film (12% yield).

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.27-7.15 (m, 2H), 6.95-6.82 (m, 3H), 4.85 (protons in the water peak, 4H), 4.78-4.63 (m, 2H), 4.58-4.21 (m, 1H), 4.23-4.12 (m, 2H) 3.53-3.35 (m, 2H), 1.81-1.68 (m, 1H), 1.68-1.24 (m, 2H), 0.98-0.83 (m, 6H);

MS (ESI<sup>+</sup>) *m/z* 404 [M+H]<sup>+</sup>.

**Example 5** (2*R*)-2-([2-Amino-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol

**(a)** (2*R*)-2-([2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino)-4-methylpentan-1-ol

5-(Benzylthio)-7-chloro[1,3]thiazolo[4,5-*d*]pyrimidin-2-amine (WO 00/09511) (1.5 g, 4.86 mmol), *N*-ethyl-*N,N*-diisopropylamine(DIPEA) (691 mg, 5.35 mmol) and (*R*)-*N*-

methyleucinol (Aitali, M.; Allaoud, S.; Karim, A.; Meliet, C.; Mortreux, A. *Tetrahedron: Asymmetry* 2000, 11, 1367-1374) (956 mg, 7.29 mmol) were mixed in 1-methyl-2-pyrrolidinone (NMP) (7.5 mL). The resulting solution was stirred at 110 °C under a nitrogen atmosphere for 2 days. After cooling to RT the reaction mixture was poured onto ice. The resulting yellow precipitate was collected by filtration, washed with water and dried *in vacuo*. The crude product was purified by column chromatography on silica (CH<sub>2</sub>Cl<sub>2</sub>:EtOAc 50:50 to 0:100) to give 1.42 g (72% yield) of the title compound as a pale yellow solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.97 (br s, 2H), 7.40 (m, 2H), 7.28 (m, 2H), 7.21 (m, 1H), 4.73 (dd, 1H), 4.64 (br s, 1H), 4.32 (br s, 2H), 3.52-3.37 (m, 2H), 3.00 (s, 3H), 1.55-1.35 (m, 2H), 1.31-1.22 (m, 1H), 0.88 (d, 3H), 0.80 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 404 [M+H]<sup>+</sup>.

(b) (2R)-2-[[2-Amino-5-(benzylsulfonyl)[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol

Oxidation of the product from step (a) according to the procedure described in Example 1, step (a), gave the title compound as an off-white solid in 80% yield.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 8.32 (br s, 2H), 7.41-7.29 (m, 5H), 4.87 (d, 1H), 4.78 (d, 1H) overlapping with 4.72 (br s, 1H), 3.60-3.41 (m, 2H), 3.11 (s, 3H), 1.60-1.39 (m, 2H), 1.35-1.25 (m, 1H), 0.90 (d, 3H), 0.85 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 436 [M+H]<sup>+</sup>.

(c) (2R)-2-[[2-Amino-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol

2-Methylbenzyl alcohol (141 mg, 1.15 mmol) was dissolved in dry THF (200 µl) under a nitrogen atmosphere and the solution was cooled to -20 °C. *n*-Butyl lithium (1.6M in hexane, 360 µl, 0.58 mmol) was added dropwise and the resulting solution was stirred for 10 min. The product of step (b) (50 mg, 0.12 mmol) was added and the reaction mixture was heated to 50 °C for 3 h. After cooling to RT, aqueous NH<sub>4</sub>Cl followed by EtOAc were added and the phases were separated. The water phase was extracted three times with EtOAc and the combined organic extracts were dried over anhydrous MgSO<sub>4</sub>, filtered and

concentrated. Purification by preparative HPLC (eluent CH<sub>3</sub>CN:0.1M NH<sub>4</sub>OAc 30:70 to 70:30) gave the title compound as an off-white solid (3 mg, 6% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.89 (br s, 2H), 7.37 (d, 1H), 7.25-7.14 (m, 3H), 5.27 (s, 2H), 4.76-4.61 (br s, 1H) overlapping with δ 4.72 (br s, 1H), 3.52-3.37 (m, 2H), 3.01 (s, 3H), 2.32 (s, 3H), 1.56-1.37 (m, 2H), 1.33-1.23 (m, 1H), 0.87 (d, 3H), 0.82 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 402 [M+H]<sup>+</sup>.

The compounds of Examples 6 to 9 were prepared using the general method of Example 5, step (c), but replacing benzyl alcohol with the appropriate alcohol.

**Example 6** (2R)-2-[(2-Amino-5-[(4-chlorobenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol

Off-white solid (5.7 mg, 12% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.90 (br s, 2H), 7.48-7.39 (m, 4H), 5.27 (s, 2H), 4.77-4.68 (br s, 1H), 4.67-4.54 (br s, 1H), 3.52-3.37 (m, 2H), 3.00 (s, 3H), 1.55-1.35 (m, 2H), 1.33-1.22 (m, 1H), 0.87 (d, 3H), 0.80 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 422 [M+H]<sup>+</sup>.

**Example 7** (2R)-2-[(2-Amino-5-[(3-chlorobenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol

Obtained as an off-white solid (3.4 mg, 7% yield) by using a procedure analogous to the one described in Example 5, step (c), with the exception that lithium diisopropyl amide (LDA) was used as base (at -78 °C) instead of n-butyl lithium.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.91 (br s, 2H), 7.48-7.33 (m, 4H), 5.29 (s, 2H), 4.71 (t, 1H), 4.62 (br s, 1H), 3.52-3.36 (m, 2H), 3.00 (s, 3H), 1.56-1.35 (m, 2H), 1.33-1.21 (m, 1H), 0.86 (d, 3H), 0.79 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 422 [M+H]<sup>+</sup>.

**Example 8** (2R)-2-[(2-amino-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol



Obtained as an off-white solid (6.0 mg, 12% yield) by using a procedure analogous to the one described in Example 5, step (c), with the exception that LDA was used as base (at -78 °C) instead of n-butyl lithium.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.88 (br s, 2H), 7.39-7.26 (m, 2H), 7.06-6.99 (m, 1H), 6.97-6.90 (m, 1H), 5.26 (s, 2H), 4.71 (br s, 1H) overlapping with 4.66 (br s, 1H), 3.81 (s, 3H), 3.52-3.36 (m, 2H), 3.00 (s, 3H), 1.56-1.37 (m, 2H), 1.33-1.22 (m, 1H), 0.88 (d, 3H), 0.81 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 418 [M+H]<sup>+</sup>.

10 **Example 9** (2R)-2-[(2-Amino-5-(benzyloxy))[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol

Off-white solid (7.6 mg, 9% yield).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 7.89 (br s, 2H), 7.45-7.26 (m, 5H), 5.28 (s, 2H), 4.72 (br s, 1H) overlapping with 4.64 (br s, 1H), 3.52-3.36 (m, 2H), 3.00 (s, 3H), 1.56-1.37 (m, 2H), 1.33-1.24 (m, 1H), 0.88 (d, 3H), 0.82 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 388 [M+H]<sup>+</sup>.

**Example 10** (2R)-[2-Amino-5-[(4-bromo-2-fluorobenzyl)-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol

20 **(a)** (2R)-2-[(2-Amino-5-mercapto[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol

A three-neck round bottomed flask was immersed in a dry ice/ethanol cooling bath and equipped with a dry ice/ethanol condenser. The system was flushed with nitrogen and ammonia (approximately 50 mL) was condensed into the flask. The product from Example 5, step (a) (1 g, 2.5 mmol) was added to the flask, resulting in a clear yellow solution. Small pieces of sodium metal (size 2-3 mm) was added one by one to the reaction mixture. When a persistent blue color (>20 sec) appeared, a spoon of solid NH<sub>4</sub>Cl was added to quench the reaction. The ammonia was evaporated. Water (50 mL) was added and the mixture was neutralized with aq 1M HCl until pH 7. The precipitated yellow solid was

collected by filtration, washed with water and dried *in vacuo* to yield 630 mg of the title compound (80% yield).

$^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  12.78 (br s, 1H), 8.43 (br s, 2H), 4.84 (br, 2H), 3.52-3.38 (m, 2H), 3.01 (s, 3H), 1.55-1.33 (m, 2H), 1.32-1.20 (m, 1H), 0.87 (m, 6H);

5 MS (ESI $^+$ )  $m/z$  314  $[\text{M}+\text{H}]^+$ .

(b) (2R)-2-[[2-Amino-5-[(4-bromo-2-fluorobenzyl)thio][1,3]thiazolo[4,5- $d$ ]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol

The product from step (a) (300 mg, 0.96 mmol) and 4-bromo-2-fluorobenzyl bromide (257  
10 mg, 0.96 mmol) were dissolved in DMSO (2.5 mL) under nitrogen. DIPEA (124 mg, 0.96 mmol) was added and the resulting solution was stirred at RT for 30 min. The reaction mixture was poured onto ice and the pale yellow precipitate was collected by filtration and washed with water. After drying *in vacuo* the crude product was purified by column chromatography on silica ( $\text{CH}_2\text{Cl}_2$ :EtOAc 70:30 to 30:70) resulting in 366 mg (76% yield)  
15 of the title compound as an off-white solid.

$^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  8.00 (br s, 2H), 7.50 (m, 2H), 7.33 (dd, 1H), 4.73 (br s, 1H), 4.61 (br s, 1H), 4.30 (s, 2H), 3.50-3.35 (m, 2H), 2.98 (s, 3H), 1.53-1.33 (m, 2H), 1.29-1.20 (m, 1H), 0.85 (d, 3H), 0.79 (d, 3H) MS (ESI $^+$ )  $m/z$  500, 502  $[\text{M}+\text{H}]^+$ .

20 (c) (2R)-[[2-Amino-5-[(4-bromo-2-fluorobenzyl)-(R $_S$ ,S $_S$ )-sulfinyl][1,3]thiazolo[4,5- $d$ ]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol

The product from step (b) (50 mg, 0.10 mmol) was dissolved in MeOH (5 mL). Potassium peroxymonosulfate (Oxone, 74 mg, 0.12 mmol) was added and the resulting  
inhomogeneous mixture was stirred at RT for 3 h. The reaction mixture was poured onto  
25 ice and the white precipitate was collected by filtration, washed with water and dried *in vacuo*. The crude product was purified by column chromatography on silica ( $\text{CH}_2\text{Cl}_2$ :EtOAc 40:60 to 0:100, followed by EtOAc:MeOH 95:5) resulting in 35 mg (68% yield) of the title compound as a white solid (1:1 mixture of two unresolved diastereoisomers).

30  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  8.19 (br s, 2H), 7.48 (m, 1H), 7.33 (m, 1H), 7.13 (m, 1H), 4.78 (m, 1H), 4.67 (br s, 1H), 4.41 (d, 1H), 4.22 (d, 1H in one diastereomer), 4.19 (d, 1H in one

diastereomer), 3.54-3.38 (m, 2H), 3.014 (s, 3H in one diastereomer) overlapping with 3.008 (s, 3H in one diastereomer), 1.55-1.15 (m, 3H), 0.85 (m, 6H);  
MS (ESI<sup>+</sup>)  $m/z$  516, 518 [M+H]<sup>+</sup>.

5

**Example 11** (2R)-2-[(2-Amino-5-{[2-(4-bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl}][1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol

(a) 1-Bromo-4-(2-bromoethyl)benzene

10 To a solution of 2-(4-bromophenyl)ethanol (1.2 g, 6.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at RT under nitrogen was added CBr<sub>4</sub> (1.98 g, 5.8 mmol) and PPh<sub>3</sub> (1.57 g, 5.8 mmol). After stirring at RT for 18 h the reaction mixture was concentrated and the residue diluted with Et<sub>2</sub>O (30 mL) resulting in precipitation of triphenylphosphine oxide. The ethereal solution was decanted, evaporated and purified by flash chromatography (silica, hexane) to provide  
15 the title compound as a clear oil (59%).

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 7.45 (d, 2 H), 7.15 (d, 2 H), 3.51 (t, 2 H), 3.17 (t, 2 H);

<sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>) δ 138.1, 133.4, 131.2, 122.5, 38.5, 27.2.

(b) (2R)-2-[(2-Amino-5-{[2-(4-bromophenyl)ethyl]thio}][1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol

20 The title compound was obtained as an off-white solid in 40% yield from the product of step (a) and (2R)-2-[(2-amino-5-mercapto[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol (WO 0276990 A1) by using the procedure described in Example 10, step (b), with the exception that the product was purified by preparative HPLC.

25 <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>) δ 7.98 (s, 2H), 7.47 (d, 2H), 7.25 (d, 2H), 6.89 (d, 1H), 4.70 (t, 1H), 4.29 (br s, 1H), 3.45-3.28 (m, 2H, obscured by water peak), 3.24 (t, 2H), 2.94 (t, 2H), 1.62-1.57 (m, 1H), 1.46-1.34 (m, 2H), 0.86 (d, 3H), 0.82 (d, 3H);

MS (ESI<sup>+</sup>)  $m/z$  482, 484 [M+H]<sup>+</sup>.

30 (c) (2R)-2-[(2-Amino-5-{[2-(4-bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl}][1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol

The title compound was obtained as a white solid (1:1 mixture of two unresolved diastereoisomers) from the product of step (b), by following the procedure described in Example 10, step (c) with the exceptions that the reaction was run at 5 °C and that the product was purified by preparative HPLC.

- 5 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 8.07 (s, 2H), 7.31 (d, 2H), 7.05 (t, 2H), 4.59 (br s, 1H), 4.15 (br s, 1H), 3.28-3.19 (m, 2H, obscured by water peak), 3.19-3.05 (m, 2H obscured by water peak), 2.89-2.82 (m, 2H), 2.79-2.73 (m, 1H), 2.67-2.62 (m, 1H), 1.49-1.44 (m, 1H), 1.33-1.24 (m, 2H), 0.75-0.67 (m, 6H);  
MS (ESI+) *m/z* 498, 500 [M+H]<sup>+</sup>.

10

**Example 12** (2R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl}][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-4-methylpentan-1-ol

- 15 (a) (2R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]thio}][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-4-methylpentan-1-ol

The title compound was obtained as a white solid in 67% yield by following the procedure described in Example 11, step (b), but replacing 1-(2-bromoethyl)-3-chlorobenzene with 1-bromo-2-(2-bromoethyl)benzene (US 6,284,796).

- 20 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 7.97 (s, 2H), 7.59 (dd, 1H), 7.41 (dd, 1H), 7.34 (dt, 1H), 7.18 (dt, 1H), 6.87 (d, 1H), 4.66 (t, 1H), 4.29 (br s, 1H), 3.42-3.30 (m, 2H), 3.27 (t, 2H), 3.09 (t, 2H), 1.67-1.54 (m, 1H), 1.47-1.32 (m, 2H), 0.85 (d, 3H), 0.83 (d, 3H);  
MS (ESI+) *m/z* 482, 484 [M+H]<sup>+</sup>.

- 25 (b) (2R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-(R<sub>S</sub>,S<sub>S</sub>)-sulfinyl}][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)amino]-4-methylpentan-1-ol

The title compound was obtained as a white solid (25% yield; 1:1 mixture of two unresolved diastereoisomers) from the product of step (a), by following the procedure described in Example 11, step (c).

- 30 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 8.20 (s, 2H), 7.56 (d, 1H), 7.35-7.26 (m, 3H), 7.16 (dt, 1H), 4.70 (unresolved t, 1H), 4.28 (br s, 1H), 3.47-3.29 (m, 2H), 3.28 (m, 2H in one diastereomer, obscured by the water peak), 3.22-3.08 (m, 2H), 2.91-2.83 (m, 2H in one diastereomer),

1.64-1.54 (m, 1H), 1.49-1.30 (m, 2H), 0.85 (t, 6H, in one diastereomer), 0.84 (d, 3H in one diastereomer), 0.79 (d, 3H in one diastereomer);

MS (ESI+)  $m/z$  498, 500  $[M+H]^+$ .

5 **Example 13** (R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-( $R_S,S_S$ )-sulfinyl}] [1,3]thiazolo[4,5- $d$ ]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol

(a) (2R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]thio}] [1,3]thiazolo[4,5- $d$ ]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol

10 The title compound was obtained as a solid in 66% yield from the product of Example 10, step (a), by following the procedure described in Example 11, step (b), but replacing 1-(2-bromoethyl)-3-chlorobenzene with 1-bromo-2-(2-bromoethyl)benzene (see Example 12, step (a)).

$^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$  7.97 (s, 2H), 7.60 (dd, 1H), 7.41 (dd, 1H), 7.37 (dt, 1H), 7.18 (dt, 1H), 4.75 (t, 1H), 4.68 (br s, 1H), 3.28 (t, obscured by the water peak, 2H), 3.09 (t, 2H), 3.02 (s, 3H), 1.57-1.42 (m, 2H), 1.32-1.22 (m, 1H), 0.87 (d, 3H), 0.82 (d, 3H);

MS (ESI+)  $m/z$  496, 498  $[M+H]^+$ .

(b) (R)-2-[(2-Amino-5-{[2-(2-bromophenyl)ethyl]-( $R_S,S_S$ )-sulfinyl}] [1,3]thiazolo[4,5- $d$ ]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol

20 The title compound was obtained as a clear film (40% yield; 1:1 mixture of two unresolved diastereoisomers) from the product of step (a), by following the procedure described in Example 11, step (c).

$^1\text{H-NMR}$  (CD $_3$ OD)  $\delta$  7.50 (app d, 1H), 7.29 (app d, 1H), 7.32 (app t, 1H), 7.09 (app t, 1H), 4.84 (obscured by the water peak, 3H), 4.56 (br s, 1H), 3.65-3.57 (m, 2H), 3.55-3.34 (m, 2H), 3.30 (s, 3H), 3.28-3.20 (m, 2H in one diastereomer, obscured by the MeOH peak), 3.06-2.93 (m, 2H in one diastereomer), 1.62-1.42 (m, 2H), 1.36-1.24 (m, 1H), 0.95-0.85 (m, 6H);

MS (ESI+)  $m/z$  512, 514  $[M+H]^+$ .

**Example 14** 2-[(2,3-Difluorobenzyl)oxy]-4-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8H)-one

(a) 2-[(2,3-Difluorobenzyl)sulfonyl]-4-[[[(1R)-1-(hydroxymethyl)-3-

5 methylbutyl]amino]pteridin-7(8H)-one

2-[(2,3-Difluorobenzyl)thio]-4-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8H)-one (WO 01/062758) (1.0 g, 2.37 mmol) was dissolved in CH<sub>3</sub>CN (120 mL) and water (80 mL). Potassium peroxymonosulfate (Oxone, 3.38 g, 5.50 mmol) was added and the resulting slurry was stirred at RT for 16 h. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution was added and the CH<sub>3</sub>CN  
10 was evaporated *in vacuo*. The residue was poured onto ice and the precipitate was collected by filtration, washed with water and dried *in vacuo* at 40 °C overnight resulting in 891 mg (83%) of the title compound as an off-white solid.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 13.5-13.0 (br s, 1H), 8.05 (br s, 1H), 7.91 (s, 1H), 7.47 (app q, 1H), 7.30-7.18 (m, 2H), 4.98 (dd, 2H), 4.83 (t, 1H), 4.41-4.38 (m, 1H), 3.55-3.35 (m, 2H), 1.60-  
15 1.50 (m, 2H), 1.41-1.35 (m, 1H), 0.88 (d, 3H), 0.87 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 454 [M+H]<sup>+</sup>.

(b) 2-[(2,3-Difluorobenzyl)oxy]-4-[[[(1R)-1-(hydroxymethyl)-3-

20 Solid NaH (17 mg, 0.7 mmol, 7 eq.) was added to a stirred solution of 2,3-difluorobenzyl alcohol (0.10 g, 0.7 mmol, 7 eq.) in dry benzene (5 mL) at 0 °C. The solution was allowed to reach RT over 15 min. The product from step (a) (45 mg, 0.1 mmol, 1 eq.) was added as a solid and the mixture was heated to reflux for 1 h. After cooling to RT, the reaction was quenched by addition of saturated aqueous NH<sub>4</sub>Cl (1 mL). The mixture was partitioned  
25 between EtOAc (10 mL) and water (10 mL). The organic phase was separated, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The oily residue was purified by preparative HPLC to give the title compound as an off-white solid (4.5 mg, 11% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.80-9.20 (br s, 1H), 7.80 (s, 1H), 7.69-7.29 (m, 3H), 6.50 (m, 1H), 5.49 (s, 2H), 4.41 (m, 1H), 3.78 (dd, 1H), 3.64 (dd, 1H), 1.68-1.48 (m, 3H), 0.95 (d, 3H),  
30 0.91 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 406 [M+H]<sup>+</sup>.

The compounds of Examples 15 to 22 were prepared using the general method of Example 14, step (b), but replacing 2,3-difluorobenzyl alcohol with the appropriate alcohol.

5 **Example 15** 4-[[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-2-[(3-methoxybenzyl)oxy]pteridin-7(8H)-one

Off-white solid (3.6 mg, 9% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.90-9.24 (br s, 1H), 7.84 (s, 1H), 7.39-7.23 (m, 2H), 6.92-6.80 (m, 2H), 6.48 (m, 1H), 5.52 (s, 2H), 4.44 (m, 1H), 3.73 (dd, 1H), 3.51 (s, 3H), 3.48 (dd, 1H),  
10 1.70-1.49 (3H), 0.96 (d, 3H), 0.91 (d, 3H);  
MS (ESI<sup>+</sup>) *m/z* 400 [M+H]<sup>+</sup>.

**Example 16** 2-[(2-Chloro-3-methoxybenzyl)oxy]-4-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8H)-one

15 Off-white solid (3.9 mg, 9% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.02-9.54 (br s, 1H), 7.85 (s, 1H), 7.30-7.06 (m, 3H), 6.46 (m, 1H), 5.50 (s, 2H), 4.43 (m, 1H), 3.73 (dd, 1H), 3.57 (s, 3H), 3.51 (dd, 1H), 1.76-1.43 (m, 3H), 0.96 (d, 3H), 0.93 (d, 3H);  
MS (ESI<sup>+</sup>) *m/z* 434 [M+H]<sup>+</sup>.

20

**Example 17** 4-[[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-2-(2-phenylethoxy)pteridin-7(8H)-one

Off-white solid (6.5 mg, 17% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.00-9.51 (br s, 1H), 7.82 (s, 1H), 7.32-7.11 (m, 5H), 6.45 (m, 1H),  
25 4.82 (t, 2H), 4.43 (m, 1H), 3.73 (dd, 1H), 3.57-3.50 (m, 3H), 1.79-1.43 (m, 3H), 0.94 (d, 3H), 0.89 (d, 3H);  
MS (ESI<sup>+</sup>) *m/z* 384 [M+H]<sup>+</sup>.

**Example 18** 4-[[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-2-(2-phenoxyethoxy)pteridin-7(8H)-one

30

Off-white solid (10% yield).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ 7.78 (s, 1H), 7.25 (app t, 2H), 6.19 (app t, 3H), 4.71 (obscured by protons in the water peak, 3H), 4.70 (t, 2H), 4.45 (septet, 1H), 4.31 (t, 2H) 3.62 (d, 2H), 1.74-1.64 (m, 1H), 1.64-1.56 (m, 1H), 1.52-1.42 (m, 1H), 0.96 (d, 3H), 0.94 (m, 3H); MS (ESI+) *m/z* 400 [M+H]<sup>+</sup>.

5

**Example 19** 2-[(2-Chlorobenzyl)oxy]-4-[[[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8*H*)-one

Off-white solid (5.6 mg, 14% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.5-8.0 (br s, 1H), 7.81 (s, 1H), 7.52-7.50 (m, 2H), 7.40-7.36 (m, 2H),  
6.50 (d, 1H), 5.49 (app t, 2H), 4.45-4.40 (m, 1H), 3.78 (dd, 1H), 3.64 (dd, 1H), 1.68-1.48  
(m, 3H), 0.95 (d, 3H), 0.91 (d, 3H);  
MS (ESI<sup>+</sup>) *m/z* 404 [M+H]<sup>+</sup>.

**Example 20** 2-[(4-Chlorobenzyl)oxy]-4-[[[(1*R*)-1-(hydroxymethyl)-3-  
15 methylbutyl]amino]pteridin-7(8*H*)-one

Off-white solid (1.2 mg, 3% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.5-9.0 (br s, 1H), 7.83 (s, 1H), 7.38 (d, 2H), 7.33 (d, 2H), 6.50 (d, 1H), 5.35 (app t, 2H), 4.42-4.39 (m, 1H), 3.79 (dd, 1H), 3.66 (dd, 1H), 1.70-1.47 (m, 3H), 0.97 (d, 3H), 0.93 (d, 3H);

20 MS (ESI<sup>+</sup>) *m/z* 404 [M+H]<sup>+</sup>.

**Example 21** 4-([(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino)-2-[(4-methylbenzyl)oxy]pteridin-7(8*H*)-one

Off-white solid (1.2 mg, 3% yield).

25 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.0-8.75 (br s, 1H), 7.80 (s, H), 7.32 (d, 2H), 7.15 (d, 2H), 6.46 (d, 1H), 5.35 (app t, 2H), 4.44-4.40 (m, 1H), 3.79 (dd, 1H), 3.64 (dd, 1H), 2.34 (s, 3H), 1.70-1.48 (m, 3H), 0.96 (d, 3H), 0.93 (d, 3H);  
MS (ESI<sup>+</sup>) *m/z* 384 [M+H]<sup>+</sup>.



**Example 22** 4-[(1*R*)-1-(Hydroxymethyl)-3-methylbutyl]amino}-2-[(3-methylbenzyl)oxy]pteridin-7(8*H*)-one

Off-white solid (1.5 mg, 4% yield).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.5-9.0 (br s, H), 7.79 (s, 1H), 7.26-7.21 (m, 3H), 7.11-7.10 (m, 1H),  
5 6.51 (m, 1H), 5.35 (app t, 2H), 4.44-4.42 (m, 1H), 3.81 (dd, 1H), 3.65 (dd, 1H) 2.33 (s,  
3H), 1.71-1.44 (m, 3H), 0.96 (d, 3H), 0.93 (d, 3H);

MS (ESI<sup>+</sup>) *m/z* 384 [M+H]<sup>+</sup>.

**Example 23** 2-[(3-Chlorobenzyl)oxy]-4-[(1*S*,2*S*)-2-hydroxy-1-(hydroxymethyl)propyl]amino}-7-oxo-7,8-dihydropteridine-6-carboxamide

**(a)** Methyl 4-amino-2-(benzylthio)-7-oxo-7,8-dihydropteridine-6-carboxylate

Sodium metal (2.3 g, 100 mmol) was dissolved in MeOH (450 mL) and 2-benzylthio-  
4,5,6-triaminopyrimidine (Berezovskii, Jurkewitsch, *J. Gen. Chem. USSR (Engl. Transl.)*  
15 **1962**, 32, 1637) (4.6 g, 18 mmol) was added. The mixture was stirred at RT for 20 min,  
then dimethyl ketomalonate (10.6 g, 72.5 mmol) was added dropwise, and the mixture was  
stirred for another 4.5 h. Water (300 mL) was added, and the pH was adjusted to 5 by  
dropwise addition of conc. aqueous HCl. The precipitate formed was filtered off, washed  
with water and dried overnight *in vacuo* to give 4.46 g (70%) of the title compound.

20 <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 13.00 (s, 1H), 8.03 (br s, 1H), 7.85 (br s, 1H), 7.49-7.21 (m, 5H),  
4.36 (s, 2H), 3.84 (s, 3H);

MS (ESI<sup>+</sup>) *m/z* 344 [M+H]<sup>+</sup>.

**(b)** Methyl 2-(benzylthio)-4-bromo-7-oxo-7,8-dihydropteridine-6-carboxylate

25 The product of step (a) (5.0 g, 14.6 mmol) was dissolved in a mixture of bromoform (100  
mL) and DMF (100 mL). The resulting suspension was homogenized at 110 °C and  
isoamyl nitrite (23 mL) was added dropwise over 10 min. After the addition was complete  
the mixture was cooled to RT in an ice bath and then evaporated *in vacuo* (oil pump).

EtOAc was added to the residue, and the mixture was stirred for 2 h. The precipitate  
30 formed was filtered off, the EtOAc layer was evaporated and the resulting crude product

was purified by flash chromatography (hexanes:EtOAc 1:1) to give 1.42 g (24%) of the title compound.

MS (ESI<sup>+</sup>) *m/z* 407, 409 [M+H]<sup>+</sup>.

5    (c) Methyl 2-(benzylthio)-4-[[[(1*S*,2*S*)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-7-oxo-7,8-dihydropteridine-6-carboxylate

The product of step (b) (759 mg, 1.86 mmol) was dissolved in of 1-methyl-2-pyrrolidinone (NMP) (5 mL), and *N*-ethyl-*N,N*-diisopropylamine (DIPEA) (1.2 mL, 7.0 mmol) and *D*-threoninol (196 mg, 1.86 mmol) were added. The resulting mixture was stirred at 80 °C  
10    for 18 h. After addition of water (10 mL) the pH was adjusted to 5 by addition of HOAc. The precipitate formed was filtered off, washed with water and dried to give 739 mg (92%) of the title compound, which was used in the subsequent step without further purification.  
MS (ESI<sup>+</sup>) *m/z* 432 [M+H]<sup>+</sup>.

15    (d) 2-(Benzylthio)-4-[[[(1*S*,2*S*)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-7-oxo-7,8-dihydropteridine-6-carboxamide

The product of step (c) (1.0 g, 2.32 mmol) was dissolved in MeOH (40 mL), and ammonia gas was bubbled through the solution for 24 h. The reaction mixture was evaporated to give 0.92 g (95% yield) of the title compound, which was used in the subsequent step  
20    without further purification.  
MS (ESI<sup>+</sup>) *m/z* 417 [M+H]<sup>+</sup>.

(e) 2-(Benzylsulfonyl)-4-[[[(1*S*,2*S*)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-7-oxo-7,8-dihydropteridine-6-carboxamide

25    The product from step (d) (208 mg, 0.5 mmol) was dissolved in MeOH:water (3:1, 12 mL), and potassium peroxymonosulfate (Oxone, 768 mg, 1.1 mmol) was added. The reaction mixture was stirred for 12 h at RT. The MeOH was evaporated *in vacuo* without heating. Water (2 mL) was added to the residue, which was then left at 4 °C for 12 h. The precipitate formed was filtered off, washed with water and dried to give 504 mg (61%  
30    yield) of the title compound, which was used in the subsequent step without further purification.

MS (ESI<sup>+</sup>)  $m/z$  449 [M+H]<sup>+</sup>.

(f) 2-[(3-Chlorobenzyl)oxy]-4-[[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]-7-oxo-7,8-dihydropteridine-6-carboxamide

5 Toluene (150  $\mu$ L) was added to NaH (168 mg, 7.0 mmol; 60% in oil, washed by hexanes), followed by addition of 3-chlorobenzyl alcohol (1.0 g, 7.0 mmol). The mixture was stirred at RT until no further gas evolution was observed (*ca.* 40 min). The product from step (e) (55.6 mg, 0.124 mmol) was added, and the resulting mixture was stirred at 60 °C for 2 h. Saturated aqueous NH<sub>4</sub>Cl was added and the mixture was stirred for another 30 min at 60  
10 °C. After cooling to RT, the organic phase was separated and triturated with a mixture of Et<sub>2</sub>O:hexanes (3:1). The precipitate formed was filtered off and purified by preparative HPLC (eluent CH<sub>3</sub>CN/0.1M NH<sub>4</sub>OAc 30:70 to 70:30) to give 5 mg (9%) of the title compound as an off-white solid.

<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  7.71 (br s, 1H), 7.60-7.30 (m, 4H), 5.42-5.28 (m, 2H), 4.97 (d, 1H),  
15 4.82 (t, 1H), 4.13-3.98 (m, 2H), 3.65-3.50 (m, 2H), 1.06 (d, 3H);

MS (ESI<sup>+</sup>)  $m/z$  435 [M+H]<sup>+</sup>.

Example 24 2-[(2,3-Difluorobenzyl)-(R<sub>s</sub>,S<sub>c</sub>)-sulfinyl]-4-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8H)-one

20 2-[(2,3-Difluorobenzyl)thio]-4-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]pteridin-7(8H)-one (WO 01/062758) (100 mg, 0.24 mmol) was dissolved in MeOH (18 mL), and water (6 mL) was added. Potassium peroxymonosulfate (Oxone, 150 mg, 0.25 mmol) was added and the reaction was stirred at RT for 2 h. The reaction mixture was poured into water and extracted with EtOAc, dried (MgSO<sub>4</sub>), filtered and concentrated *in vacuo*. Et<sub>2</sub>O  
25 was added to the remains, and the yellow solid was filtered off. The crude solid was purified by preparative thin layer chromatography (10% MeOH in EtOAc) to give the title compound as a white solid (unresolved mixture of diastereomers 1:1; 11 mg, 11% yield).

<sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  13.16 (s, 1H in one diastereomer), 13.12 (s, 1H in one diastereomer), 8.17 (t, 1H), 8.034 (s, 1H in one diastereomer) 8.027 (s, 1H in one  
30 diastereomer), 7.44-7.33 (m, 1H), 7.19-7.05 (m, 1H), 7.01-6.92 (m, 1H), 4.85-4.78 (m,

1H), 4.60 (t, 2H in one diastereomer), 4.36 (br s, 1H), 4.33 (t, 2H in one diastereomer), 3.55-3.42 (m, 2H), 1.62-1.47 (m, 2H), 1.44-1.32 (m, 1H), 0.92-0.82 (m, 6H); MS (ESI<sup>+</sup>) *m/z* 438 [M+H]<sup>+</sup>.

5

### **Pharmacological Screens**

#### **Materials**

Recombinant human fractalkine (hCX<sub>3</sub>CL1) was purchased from PeproTech Inc., UK. Recombinant [<sup>125</sup>I]-fractalkine (human), with a specific activity of 2200 Ci/mmol, was purchased from NEN<sup>®</sup> Life Science Products, Inc., UK. Fluo4-AM was purchased from Molecular Probes, US. All other chemicals were of analytical grade.

#### **Expression of human fractalkine receptor (hCX<sub>3</sub>CR1)**

The complete human CX<sub>3</sub>CR1 cDNA (GenBank accession number U20350) was extracted from human brain mRNA (Superscript, Life Technologies) and ligated into pCR-Blunt II TOPO vector (Invitrogen). The insert corresponding hCX<sub>3</sub>CR1 was isolated and further subcloned into pcDNA3.1zeo. Plasmid DNA was prepared using Plasmid Midi Kit (Qiagen). Using Superfect Transfection Reagent (Qiagen) according to the manufacture's protocol the expression plasmid for hCX<sub>3</sub>CR1 was then introduced into human embryonic kidney suspension (HEKS) 293 cell line containing a vector for stable expression of a chimeric G-protein Gα<sub>q15</sub>. A stable clone was generated utilizing zeocin (500 µg/ml) and hygromycin (100 µg/ml) selection. For further applications the cells were maintained in Dulbecco's modified Eagle's medium/Ham's nutrient mix F12 (DMEM/F12) containing pyridoxine and supplemented with 10% (v/v) fetal bovine serum, 2mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, 250 µg/ml zeocin and 100 µg/ml hygromycin.

#### **Ligand Binding Assay**

For the competition binding assay cells were harvested in buffer containing 10 mM Tris-HCl, pH 7.4, 5 mM ethylenediaminetetra-aceticacid (EDTA) and 0.1 mg/ml bacitracin (a

protease inhibitor) and centrifuged at 300xg for 10 min. Cell pellets were then resuspended in harvesting buffer, pooled and homogenised using Dounce homogeniser. Cell membranes were centrifuged at 48000xg for 10 min and then resuspended in harvesting buffer using Ultra-Turrax T8 (IKA Labortechnik, Germany). Protein concentration was determined in microtiter plates as described by Harrington (1990, Anal. Biochem. 186, 285 – 287). Membrane aliquotes were stored at –70 °C. Receptor expression was confirmed with [<sup>125</sup>I]-fractalkine binding using whole cells. Competition binding assays were performed in 2ml 96-deep-well plates (Beckman, Germany) in a total volume of 1000 µl/well. Each well contained 10 pM [<sup>125</sup>I]-fractalkine and membrane equivalent to receptor concentration of 1 pM in assay buffer [50 mM Hepes-KOH, pH 7.4, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, 0,1 % (w/v) gelatin]. Test compounds were pre-dissolved in DMSO and added to reach a final concentration of 1 % (v/v) DMSO. The assay was initiated with the addition of membranes and incubated at 25°C for 24 h. Assay plates were filtrated with a Tomtec cell harvester (Tomtec, US) using ice-cold wash buffer (10mM Hepes-KOH pH 7.4, 500mM NaCl) and harvested onto printed filtermat B, GF/B (PerkinElmer LifeScience,US) presoaked in 0.3% polyetyhlenimine. MeltiLex solid scintillator (PerkinElmer LifeSciences,US) were melted onto filters and radioactivity was measured in a Wallac1205 Betaplate counter (PerkinElmer LifeScience, US).

### Solubility Assay

#### **Method Description**

100 µM Solutions in duplicate, prepared by dilution from a 10 mM DMSO stock solution of the test compound, were incubated in 0.1M phosphate buffer, pH 7.4, in a 96-well plate (PP plate, 350 µl U-shaped wells, COSTAR) on a plate bed shaker (IKA®-Schüttler MTS-4, IKA Labortechnik) at 300 rpm and room temperature (20-22 °C) for 24 hours.

The solutions were transferred to a MultiScreen™-R4 96-well filtration plate (LCR membrane, 0.4 µm hydrophilic PTFE, non-sterile glass-filled PP plate, 350 µl wells, Millipore) and filtered under vacuum to a 96-well collection plate (PP plate, 350 µl U-shaped wells, COSTAR), called the analyte plate, using Millipore Vacuum Manifold

equipment. The analyte plate was covered by heat-sealing with an aluminium foil coated with a PP seal layer (AB-0813, pierceable sealing foil strong, ABgene).

LC-UV-MS analysis was performed using a generic LC method.

5





Single point quantification was performed against two 100  $\mu$ M standards of the test compound dissolved in DMSO at the wavelength showing maximum UV absorbance as extracted from the DAD-trace (210 - 400 nm). The upper limit of the screen method is 100  $\mu$ M with a LOQ of 0.1  $\mu$ M.

10

### Results


When tested in the ligand binding assay, the compounds of Examples 1 to 24 gave  $K_i$  values of less than 10  $\mu$ M, indicating that they are expected to show useful therapeutic activity. Representative solubility data are shown in the following Table in which four  
15 Examples from the present application are compared with the corresponding sulphide derivatives ( $X = S$ ) from within the generic scope of WO 00/09511, WO 01/58907 and WO 01/62758:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

Compound		Solubility ( $\mu$ M)
	X = O Example 2	72.9
	X = S	0.5
	X = O Example 3	63.6
	X = S	0.3
	X = S(O) Example 13	33.8
	X = S	0.0
	X = S(O) Example 24	44.0
	X = S	1.3

Claims


1. A compound of formula (I)



(I)


wherein:

A represents a group of formula (a) or (b):



(a)

or



(b)

R<sup>1</sup> and R<sup>2</sup> independently represent H, C1 to 8 alkyl, C2 to 8 alkenyl, C2 to 8 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; the latter four groups being optionally further substituted by one or more groups selected independently from OH, C1 to 6 alkoxy, CH<sub>2</sub>OR<sup>4</sup>, NR<sup>5</sup>R<sup>6</sup>, CO<sub>2</sub>R<sup>7</sup> and CONR<sup>8</sup>R<sup>9</sup>;

R<sup>3</sup> represents C1 to 6 alkyl, C2 to 6 alkenyl, C2 to 6 alkynyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or alkynyl chain optionally including a O, NR<sup>10</sup> or S atom in the chain; said alkyl, alkenyl, alkynyl or cycloalkyl group being optionally substituted by phenyl or a 5 or 6 membered heteroaromatic ring containing 1 to



3 heteroatoms selected independently from O, S and N; said phenyl or heteroaromatic ring being optionally further substituted by one or more groups selected independently from halogen, C1 to 4 alkyl, OH, C1 to 4 alkoxy, CN, CO<sub>2</sub>R<sup>11</sup>, NR<sup>12,13</sup>, CONR<sup>14,15</sup>, SO<sub>2</sub>R<sup>16</sup>, NR<sup>17</sup>SO<sub>2</sub>R<sup>18</sup> and SO<sub>2</sub>NR<sup>19,20</sup>;

5

X represents O or S(O);

R<sup>21</sup> represents H, CH<sub>2</sub>OR<sup>24</sup>, CH<sub>2</sub>NR<sup>24,25</sup>, CO<sub>2</sub>R<sup>24</sup> or CONR<sup>24,25</sup>;

10 R<sup>22</sup> and R<sup>23</sup> independently represent H, C1 to 6 alkyl, C2 to 6 alkenyl or C3 to 7 saturated or partially unsaturated cycloalkyl; said alkyl, alkenyl or cycloalkyl group being optionally substituted by OR<sup>24</sup>, NR<sup>24,25</sup>, CO<sub>2</sub>R<sup>24</sup> or CONR<sup>24,25</sup>; or the group -NR<sup>22,23</sup> together represents a 3 to 7 membered saturated azacyclic ring optionally incorporating one further heteroatom selected from O, S(O)<sub>n</sub> and NR<sup>26</sup>; and optionally substituted by OR<sup>24</sup>,  
15 NR<sup>24,25</sup>, CO<sub>2</sub>R<sup>24</sup> or CONR<sup>24,25</sup>;

n represents an integer 0, 1 or 2;

20 R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup>, R<sup>19</sup>, R<sup>20</sup>, R<sup>24</sup>, R<sup>25</sup> and R<sup>26</sup> independently represent H or C1 to 6 alkyl;


and pharmaceutically acceptable salts thereof.

25 2. A compound according to Claim 1 wherein R<sup>1</sup> represents H or CH<sub>3</sub>.

3. A compound according to Claim 1 or Claim 2 wherein R<sup>2</sup> represents C1 to 8 alkyl substituted by OH or C3 to 7 cycloalkyl substituted by OH or CH<sub>2</sub>OR<sup>4</sup>.

4. A compound according to any one of Claims 1 to 3 wherein R3 represents C1 to 2 alkyl substituted by phenyl; said phenyl being optionally substituted by halogen, C1 to 6 alkoxy or CN.
5. A compound of formula (I), according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use as a medicament.
6. A pharmaceutical formulation comprising a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.
7. A method of treating, or reducing the risk of, a human disease or condition in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial which comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof.
8. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which antagonism of the CX<sub>3</sub>CR1 receptor is beneficial.
9. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis or pain.
10. A process for the preparation of a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the process comprises:
- (a) when X in formula (I) represents O, reaction of a compound of formula (II)

42




(II)

wherein A, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1;

with a compound of formula (III)


5



(III)

wherein R<sup>3</sup> is as defined in Claim 1 and is independent of the R<sup>3</sup> group in formula (II); or

(b) when X in formula (I) represents S(O), oxidation of a compound of formula (IV)



(IV)

10


wherein A, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1; with one equivalent of an oxidising agent;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

15

**Abstract**

There are disclosed novel compounds of formula (I)



(I)

wherein A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX<sub>3</sub>CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis and pain.